MedTrace Logo

Hemodynamic Profile of Terlipressin and Octreotide in Patients With Cirrhosis and Portal Hypertension. A Randomised, Single Blinded Clinical Trial.

NCT04353193 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2020-04-20

No results posted yet for this study

Summary

Clinical trial to compare the effects of terlipressin and octreotide in the reduction of portal hypertension measured as hepatic venous pressure gradient (HVPG) in patients with liver cirrhosis

Conditions

  • Liver Cirrhosis Portal

Interventions

DRUG

Terlipressin

Terlipressin 1mg IV bolus

DRUG

Terlipressin

Terlipressin by IV continuous infusion at a rate of 2mg/day (max 4mg/day) during 2 hours

DRUG

Octreotide

Octreotide 50mcg IV bolus plus continuous infusion at a rate of 50mcg/h during 2 hours

Sponsors & Collaborators

  • Juan A. Arnaiz

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-30
Primary Completion
2022-02-28
Completion
2022-05-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04353193 on ClinicalTrials.gov